Lanreotide Sun (Lanreotide Acetate)

Lanreotide Sun is used to control hormone‑driven conditions within the endocrine and neuroendocrine disease spectrum.

• Acromegaly: reduces growth hormone and IGF‑1 levels, helping to control disease activity and improve symptoms.
• Carcinoid tumors: inhibits secretion of vasoactive peptides, aiding in symptom control of functional neuroendocrine tumors.
• Gastroenteropancreatic neuroendocrine tumors: suppresses hormone production and may limit tumor progression in hormone‑secreting gastrointestinal tumors.

• Lanreotide acetate binds with high affinity to somatostatin receptor subtypes 2 and 5 on target cells. This receptor activation inhibits adenylate cyclase activity, reduces intracellular calcium, and suppresses the release of several hormones including growth hormone, insulin, glucagon, and various gastrointestinal peptides. The resulting decline in circulating IGF‑1 and other trophic factors helps control hormone‑dependent tumor growth and metabolic effects.

Lanreotide Sun may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the subcutaneous injection site.
• Gastrointestinal disturbances: nausea, abdominal pain, diarrhea, or constipation.
• Hyperglycemia: elevated blood glucose levels, particularly in patients with diabetes.
• Gallbladder abnormalities: formation of gallstones or biliary sludge.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
• Severe hypersensitivity reactions: anaphylaxis, angioedema, or skin rash requiring immediate medical attention.
• Cardiac arrhythmias: irregular heart rhythms that may require monitoring.

Before initiating Lanreotide Sun, clinicians should consider several precautionary measures to ensure safe use.

• Glucose monitoring: regularly assess blood glucose, especially in diabetic patients, as the drug can alter glycemic control.
• Gallbladder assessment: evaluate for gallstones or biliary disease prior to treatment and monitor during therapy.
• Pancreatitis vigilance: discontinue if signs of acute pancreatitis develop.
• Renal and hepatic function: adjust therapy in patients with severe impairment after clinical evaluation.
• Hypersensitivity: avoid use in individuals with known allergy to lanreotide or any excipients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide Sun can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Concomitant somatostatin analogs: additive hormonal suppression may increase risk of severe side effects.
• Cyclosporine: may raise lanreotide plasma concentrations, requiring dose adjustment.
• Insulin or oral hypoglycemic agents: enhanced glucose‑lowering effect may cause hypoglycemia; monitor closely.

Moderate Interactions (Monitor Closely)

• Quinidine: may alter lanreotide metabolism, necessitating therapeutic drug monitoring.
• Warfarin: potential change in anticoagulant effect; monitor INR.
• Glucocorticoids: may affect blood glucose and electrolyte balance; observe patient response.